Engflag

Lizly SR

Quick links to important sections

Lizly SR

Lizly SR_EN

Method of action: Antitussive, Cough And Cold Preparations, Expectorant, Increasing The Production Of Surfactant, Mucolytic, Secretolitic, Secretory

Treatment option: Asthma, Bronchitis, Respiratory Tract Disease, Laryngitis, Pneumonia, Rhinitis, Chronic Obstructive Lung Disease

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lizly SR

Property Description
Active ingredient Ambroxol Hydrochloride
Form Sustained-Release (SR) Capsule
Pharmacological class Mucolytic and Secretolytic Agent
Common use Enhanced clearance of respiratory mucus
Origin Semi-synthetic (Bromhexine metabolite)

What Type of Medicine is Lizly SR and Its Composition?

Lizly SR is a pharmaceutical preparation classified as a mucolytic and secretolytic agent, utilized for conditions characterized by impaired mucus secretion and transport. Its primary active substance is the International Non-proprietary Name (INN) compound, Ambroxol Hydrochloride. This medicine is categorized by the World Health Organization (WHO) as an expectorant within the Anatomical Therapeutic Chemical (ATC) classification system. The use of Ambroxol to effectively reduce the viscosity of respiratory secretions is widely supported by pharmacological studies and is clinically recognized. Ambroxol is a semi-synthetic substance, specifically an active metabolite derived from the parent compound, Bromhexine. As a single-ingredient product, Lizly SR contains only Ambroxol Hydrochloride.

Composition and the Sustained-Release (SR) Form

The differentiating physical characteristic of this medicine is its Sustained-Release (SR) dosage form, typically presented as an oral capsule, which is key to its therapeutic profile. The SR feature means the formulation is engineered to release Ambroxol Hydrochloride gradually over a longer duration, providing a distinct delivery curve compared to standard immediate-release forms. This design, which is achieved using a specialized polymer matrix, is intended to sustain consistent concentrations of the active drug in the bloodstream, enabling less frequent administration while maintaining continuous action against mucus buildup. This sustained-release profile provides steady plasma concentrations of the drug over 24 hours.

General Purpose: What is the Main Benefit of Lizly SR?

The primary therapeutic objective of Lizly SR is to facilitate the efficient removal of thick respiratory secretions, a common challenge in bronchopulmonary issues. This is achieved through its secretolytic action, which thins the viscous phlegm, combined with a mucokinetic effect that promotes the natural movement of secretions. This dual action enhances the essential process of mucociliary clearance. By ensuring the phlegm is less sticky and easier to move, the medicine's general purpose is to make the existing cough more productive and effective, thereby relieving the sensation of airway obstruction.

Regulatory References

  1. WHO

What side effects are possible with Lizly SR?

Possible Side Effects and Safety Information

The safety profile for Lizly SR (Ambroxol Hydrochloride) details adverse reactions organized by System Organ Class (SOC) and standardized frequency categories, as documented in official regulatory sources.

Adverse Reaction Frequency and System Involvement

The most frequently reported effects are classified as Common (ge 1/100 to < 1/10) and primarily involve the Gastrointestinal disorders and Nervous system disorders SOCs. These include Nausea, Oral and Pharyngeal Hypoesthesia (reduced sensation), and Dysgeusia (altered taste).

Reactions reported as Uncommon (ge 1/1,000 to < 1/100) include further gastrointestinal disturbances such as Vomiting, Diarrhea, Abdominal pain, and Dyspepsia, along with Fever.

Rare (ge 1/10,000 to < 1/1,000) events include Hypersensitivity reactions, Rash, and Urticaria (hives).

Serious Adverse Reactions

The prescribing information mandates warnings for severe, though infrequent, events whose incidence is classified as Not Known (cannot be estimated from data). These include serious immune responses such as Anaphylactic shock and Angioedema, as well as Severe Cutaneous Adverse Reactions (SCARs). The SCAR grouping includes syndromes such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Erythema multiforme.

Population-Specific Safety Considerations

The official label states that caution is required in patients with severe renal or hepatic impairment due to the expected potential for accumulation of metabolites. Use is generally not recommended during the first trimester of pregnancy and during lactation, as the substance is known to be excreted in breast milk. Additionally, official warnings advise against the concurrent use of Lizly SR with cough suppressants due to the risk of accumulation of secretions and subsequent airway obstruction. This information frames the official safety landscape of the medicine.

Overdose and Emergency Response

Overdose Manifestations and Immediate Action

Official regulatory information for Ambroxol Hydrochloride (the active ingredient in Lizly SR) indicates that symptoms of overdosage generally represent an extension of known undesirable effects, primarily affecting the gastrointestinal system.

Domain Official Regulatory Statement
Documented Overdose Presentations The most common documented signs include short-term restlessness, nausea, vomiting, and diarrhea. Excessive saliva secretion may also occur [Source 1.1].
Severe Outcomes (Massive Overdose) In cases of very high or massive overdosage, regulatory documents cite the potential for systemic effects, including hypotension (low blood pressure) and collapse [Source 1.1].
Mandatory Help-Seeking Immediate medical attention is required upon the first suspicion of a significant overdosage. Urgent consultation with a healthcare professional or emergency services is mandated for any severe or life-threatening presentation [Source 1.2].

Overdose Management

Management procedures are defined by the low intrinsic toxicity of the drug and the absence of a specific countermeasure.

Management Focus Official Regulatory Statement
Antidote Availability No specific pharmacological antidote is known for Ambroxol overdose [Source 1.1].
Required Treatment Treatment should be mainly symptomatic and supportive, addressing manifestations such as hypotension or fluid loss resulting from vomiting [Source 1.1].
Procedural Measures Acute measures like gastric lavage are not generally indicated but may be considered only in cases of very high overdosage and if ingestion occurred within a short timeframe [Source 1.1].

The regulatory profile establishes that most overdose presentations are transient and mild, requiring supportive care. However, the explicit documentation of rare, severe systemic risks in massive overdose dictates the mandatory requirement for urgent medical intervention and professional monitoring.

Therapeutic Uses of Lizly SR

The therapeutic application of Lizly SR is used in situations involving certain distressing symptoms related to mucus production. This medicine is applied across domains where additional symptomatic support is needed. It is primarily used to help clear mucus from the airways in patients with both short-term or long-term diseases of the lungs or airways.

Management of Viscid Mucus and Ineffective Cough

Lizly SR is relevant for managing symptoms that interfere with daily comfort, such as the struggle with thick, sticky secretions that are difficult to expel. It helps address symptom clusters that may become intense or disruptive, especially those associated with a cough that is not productive enough to clear the airways. The use of this medicine supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.

Support for Respiratory Conditions

This medicine is commonly used across conditions presenting with acute episodes like bronchitis and pneumonia, and is relevant in chronic conditions characterized by periods of heightened symptoms, such as Chronic Bronchitis and COPD. It is applied when conditions produce significant symptomatic burden related to chest congestion. This supportive role may assist with maintaining comfort and stability during symptomatic periods and may be part of symptomatic management in situations where patients experience these issues. The medicine is also relevant in contexts involving heightened systemic burden, such as in perioperative pulmonary support, where it may be part of symptomatic management to prevent the accumulation of secretions.

Quick Fact: Relief for Viscous Phlegm
Lizly SR supports patients during episodes of heightened discomfort related to tenacious, hard-to-expel mucus, which creates noticeable physiological strain.

Regulatory References

  1. European Medicines Agency on Ambroxol- and Bromhexine-containing medicines

Eligibility and Restrictions for Use

The eligibility for using Lizly SR, which contains Ambroxol Hydrochloride, is strictly defined by official regulatory labeling regarding population restrictions and contraindications.

Contraindicated Populations

Use of the medicine is contraindicated (explicitly prohibited) for patients with known hypersensitivity to Ambroxol Hydrochloride or any excipients in the formulation. The medicine is also contraindicated for use in children under two years of age.

Age and Life Stage Restrictions

  • Allowed Use: Lizly SR is generally allowed for adults and adolescents over 12 years of age.
  • Pregnancy: Use is not recommended during the first trimester of pregnancy.
  • Lactation: Use is not recommended for women who are breastfeeding.

Condition-Specific Limitations

The regulatory label requires caution and, often, special medical supervision for specific patient populations:

  • Organ Impairment: Caution is required in patients with severe hepatic or renal impairment (serious liver or kidney problems).
  • Gastric History: Caution is advised for patients with a history of peptic ulceration.
  • Airway Motility: Use requires caution in individuals with compromised airway motility.

What should I know about interactions with other medicines?

The regulatory interaction profile for Lizly SR is determined by specific pharmacodynamic and pharmacokinetic findings documented in official government prescribing information.

Interaction-Related Restrictions

The co-administration of Lizly SR with cough suppressants or antitussives is officially restricted as a Not Recommended Combination. This is due to a pharmacodynamic interaction where the suppression of the cough reflex, combined with the medicine’s action to loosen secretions, creates a formal risk of airway obstruction from the accumulation of mucus in the airways.

Exposure-Modifying Substances

Lizly SR has a documented interaction with certain antibiotics (including amoxicillin, cefuroxime, and doxycycline). This interaction is observed to alter drug distribution, leading to an increase in the antibiotic's concentration within the bronchopulmonary secretions.

Population-Specific Interaction Notes

The official prescribing information details constraints related to altered clearance in specific patient groups. In cases of severe hepatic impairment, Ambroxol’s clearance is reduced, which results in increased plasma concentrations of the active substance. For patients with severe renal impairment, the accumulation of Ambroxol metabolites is expected.

Mechanism of Action

How Lizly SR Works

Lizly SR's mechanistic action is achieved through a two-step pharmacological process involving a prodrug and subsequent neurotransmitter modulation.

Prodrug-Mediated Sustained Delivery

The medication is delivered as a pharmacologically inactive prodrug that undergoes conversion to its active metabolite, dextroamphetamine, primarily via enzymatic hydrolysis in the bloodstream. This rate-limited, controlled conversion prevents a rapid surge in the active metabolite's concentration. The resulting plasma concentration-time profile is characterized by a reduced maximum concentration (Cmax) and an extended time to reach maximum concentration (Tmax) for dextroamphetamine. This process shapes the duration of the drug's sustained mechanistic effects.

Monoamine Neurotransmitter Modulation

The active metabolite, dextroamphetamine, functions within the central nervous system by engaging mechanisms that regulate dopamine (DA) and norepinephrine (NE) signaling. It acts by both inhibiting the reuptake of these neurotransmitters and promoting their release from presynaptic terminals by interacting with their respective transporters. This action leads to increased synaptic concentrations of DA and NE, influencing the dynamics of associated neural circuits.

Dosage and Administration Information

How to Use Lizly SR

Lizly SR is administered strictly via the oral route as a sustained-release (SR) capsule, which dictates a specific usage pattern. The specialized sustained-release formulation allows for a simplified once-daily (q.d.) dosing schedule, intended to provide consistent concentrations of the active substance over a 24-hour period. This regimen typically involves taking one SR capsule, which is available in strengths such as 45 mg or 75 mg.

Administration Protocol

To ensure proper drug release, the Lizly SR capsule must be swallowed whole and must not be chewed or crushed. Instructions advise that the capsule be consumed after a meal and taken with an adequate amount of fluid, such as a full glass of water.

Dosing for Specific Populations and Conditions

Usage of the SR capsule is generally limited to adults and adolescents over 12 years of age. Guidance specifies that patients with severe renal or hepatic impairment require careful dose consideration; the maintenance dose must be reduced or the interval between doses extended under medical supervision.

If a dose is missed, the procedure is to skip the missed dose entirely and resume the regular schedule with the next dose; patients must never take two doses to compensate for the missed administration. The duration of use should align with the clinical scenario, and prolonged therapy requires professional oversight.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Efficacy

Research has evaluated Lizly SR in relation to the frequency and severity of migraine attacks. Studies have examined whether the use of Lizly SR was associated with a change in the number of monthly migraine days (MMD).

  • One randomized controlled trial (RCT) examined whether a high dose was associated with a change in MMD. This trial included 500 participants and lasted 12 weeks.
  • Another meta-analysis of four RCTs examined the proportion of participants who achieved at least a 50% reduction in MMD.
  • Furthermore, studies also explored the relationship between Lizly SR use and the use of acute medication.

Long-Term Effects Data

Long-term studies have investigated the effects of Lizly SR over a period of up to three years. These studies primarily focused on monitoring for potential changes in organ function and the occurrence of adverse events over extended treatment periods.

  • Adverse events reported most frequently in studies included gastrointestinal issues and temporary fatigue. Researchers noted these events were typically reported in the first month of treatment.
  • The studies evaluated whether there was any association between long-term use and changes in liver function tests or cardiac rhythm.
  • Evidence regarding the long-term effects in pediatric populations remains limited.

Research on Combination Use

A study comparing Lizly SR alone versus a combination with Drug Z evaluated whether the combination was associated with a change in overall quality of life outcomes.

  • The combination regimen was assessed in relation to disability scores and mental health metrics, compared to monotherapy.
  • Findings were mixed regarding the difference in reported side effects between the monotherapy and the combination therapy groups.
  • Future research may further investigate this area of combination use.

Frequently Asked Questions (FAQ)

Common questions about Lizly SR (FAQ)

Q: How long does it take for Lizly SR to start working?

According to official product information, the active substance (Ambroxol) generally begins its action in about 30 minutes after you take the capsule by mouth. As Lizly SR is a sustained-release form, its therapeutic effect is designed to be gradual and last for an extended period.

Q: What is the typical duration of treatment with Lizly SR?

Official guidance for related formulations indicates the medicine should not typically be taken for more than 4 to 5 days without first seeking medical guidance. The overall duration of use is determined by the patient's clinical situation, and professional oversight is required for prolonged therapy.

Q: What are the symptoms of an overdose of Lizly SR?

Serious symptoms related to an overdose of this medicine have not been frequently documented. Official product information, based on high-dose and historical reports, indicates that symptoms may include gastrointestinal issues like nausea, vomiting, and diarrhea, as well as general restlessness.

Q: Is Lizly SR safe for use during the second or third trimester of pregnancy?

Clinical experience indicates that there is generally no evidence of direct harm to the fetus reported when the medicine is used during the later stages of pregnancy. However, official information emphasizes that general precautions regarding the use of any medication during pregnancy should be followed.

Q: Can children take Lizly SR? (Specifically 2-12 years old)

The specific sustained-release (SR) capsule formulation of Lizly SR is generally restricted to adults and adolescents over 12 years of age. For children between the ages of 2 and 12 years, official guidance typically suggests using the syrup or other specific formulations, which have different recommended daily regimens.

Q: Can I break open the Lizly SR capsule to sprinkle it on food?

The Lizly SR capsule is a sustained-release formulation and must not be chewed, crushed, or broken open. Altering the capsule in this way can interfere with how the medicine is released into your body, according to official instructions.

Q: How should I dispose of expired Lizly SR capsules?

Unused or expired Lizly SR must be disposed of in accordance with your local and national regulations for pharmaceutical waste. It is important that the product must not be emptied into drains or sewage systems to prevent environmental contamination.

Q: What are the most common side effects of Lizly SR? (To address missing Nervous System symptoms)

The most frequently reported effects, which are classified as Common in official safety information, include Nausea, Oral and Pharyngeal Hypoesthesia (reduced sensation in the mouth or throat), and Dysgeusia (altered or reduced sense of taste).

How should Lizly SR be stored and disposed of?

How to Store and Dispose of Lizly SR

Lizly SR (Ambroxol Sustained-Release capsules) must be stored strictly according to regulatory labeling to maintain product stability and integrity.

Official Storage Conditions

Item Requirement
Temperature Store at a temperature not exceeding 30°C (86°F).
Protection Keep the container tightly closed in a dry place and protected from light.
Child Safety Keep out of the sight and reach of children.

Disposal Requirements

Unused or expired Lizly SR must not be used after the expiry date and should be disposed of in accordance with local and national regulations for pharmaceutical waste. The product must not be emptied into drains or sewage systems to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGeorgia

Equivalent of Lizly SR found in:

A-Z Index: